Epigenetic regulation of nkg2d ligand and the rise of nk cell-based immunotherapy for cancer treatment

HIGHLIGHTS

• What: The aim of this trial was to manage acquired resistance (advanced NSCLC) to gefitinib and also extend progression free survival (PFS) in the patient. The success of this trial provides the hope for testing NKT_cell immunotherapy in context of other EGFR-tyrosine kinase inhibitors (TKIs) and various other types of tumors. The study observed that the objective response rate (ORR) and the 1-year survival rate was higher in patients who received NK combination therapy with pembrolizumab than those who received pembrolizumab as monotherapy (ORR, 41.7% vs. 0%; 1-year survival rate, 66.7% vs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.